CC
ACHN

CQS Cayman’s Achillion Pharmaceuticals ACHN Stock Holding History

CQS Cayman’s Portfolio ACHN Stock Details ACHN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q1 		– Sell
-115,000
Closed -$1.24M – 139
2015
Q4 		$1.24M Buy
115,000
+4,800
+4% +$43.6K 0.09% 107
2015
Q3 		$761K Buy
+110,200
New +$898K 0.06% 125
2015
Q2 		– Sell
-530,000
Closed -$5.23M – 231
2015
Q1 		$5.23M Buy
+530,000
New +$6.62M 0.25% 78

Other funds holding ACHN

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
JHIU
Janus Henderson Investors US Denver, Colorado $122B AUM 18.26% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

CQS Cayman's ACHN Position: Q1 2016 in Review

CQS Cayman sold out of Achillion Pharmaceuticals (ACHN) in Q1 2016, closing a stake of 115,000 shares — an estimated $1.24M sold.

CQS Cayman first reported a position in ACHN in Q1 2015 and held it in 3 quarters. The position peaked at $5.23M in Q1 2015. 153 funds tracked by Wall St. Rank hold ACHN as of Q1 2016.

  • CQS Cayman reported no remaining Achillion Pharmaceuticals position as of Q1 2016 after selling out during the quarter.
  • CQS Cayman sold 115,000 Achillion Pharmaceuticals shares in Q1 2016, an estimated $1.24M.
  • CQS Cayman first reported a position in Achillion Pharmaceuticals in Q1 2015 and held it in 3 quarters.
  • CQS Cayman's Achillion Pharmaceuticals position peaked at $5.23M in Q1 2015.
  • 153 funds tracked by Wall St. Rank held Achillion Pharmaceuticals as of Q1 2016.

Based on CQS Cayman's 13F filing for Q1 2016, filed 4 May 2016.